Saturday, May 21, 2016 3:34:18 PM
A lot of stock start to run higher after serial of lawsuit. Meaningless this should pass 1 dollar Monday
Recent KALV News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 12:30:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:42:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:41:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:40:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:40:18 PM
- KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference • Business Wire • 04/08/2026 11:00:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:01:00 PM
- KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference • Business Wire • 03/30/2026 11:00:00 AM
- Form 10-KT - Transition reports [Rule 13a-10 or 15d-10] • Edgar (US Regulatory) • 03/25/2026 08:35:23 PM
- KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period • IH Market News • 03/25/2026 12:39:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 11:16:51 AM
- KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update • Business Wire • 03/25/2026 11:00:00 AM
- KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference • Business Wire • 03/20/2026 11:00:00 AM
- KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 • Business Wire • 03/18/2026 11:00:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/04/2026 12:00:00 PM
- KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) • Business Wire • 03/02/2026 12:00:00 PM
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences • Business Wire • 02/25/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:44:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:44:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:43:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:42:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 12:42:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 12:45:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 12:44:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2026 12:44:07 AM
